Table 2.

Annual rates of invasive breast cancer—NSABP STAR Trial (P-2)

Participant characteristic at baselineNumber of eventsRate per 1000RR*RR (95% CI)
Age at entry (years)
History of lobular carcinoma in situ
History of atypical hyperplasia
5-year predicted breast cancer risk (%)
No. 10 relatives with breast cancer

Abbreviations: CI, confidence interval; NSABP STAR, National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene; RR, risk ratio.

  • *Risk ratio for women in the raloxifene group compared to women in the tamoxifen group.

  • Rate in the tamoxifen group minus rate in the raloxifene group.